Jefferies Financial Group’s KalVista Pharmaceuticals KALV Stock Holding History

Jefferies Financial Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-158,300	Closed	-$1.83M	–	1578
2025 Q1	$1.83M	Buy	+158,300	New	+$1.62M	0.02%	604

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jefferies Financial Group's KALV Position: Q2 2026 in Review

Jefferies Financial Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 286,046 shares — an estimated $5.76M sold.

Jefferies Financial Group first reported a position in KALV in Q4 2022 and held it in 12 quarters. The position peaked at $13.2M in Q4 2023. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Jefferies Financial Group reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jefferies Financial Group sold 286,046 KalVista Pharmaceuticals shares in Q2 2026, an estimated $5.76M.
Jefferies Financial Group first reported a position in KalVista Pharmaceuticals in Q4 2022 and held it in 12 quarters.
Jefferies Financial Group's KalVista Pharmaceuticals position peaked at $13.2M in Q4 2023.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.